InnoCare Pharma Limited INCPF
Set alert
1.60 USD 0.00 0.00%
At close · Oct 30
1.60 Day range 1.60
1.55 52-week range 3.26
- YTD
- -21.95%
- 1 year
- -50.92%
- Open
- 1.60
- Prev close
- 1.60
- Mkt cap
- 2.83B
- Vol
- 200
- Avg vol
- 42
- EPS
- 0.08
- P/E
- 20.00
More statistics
- Low
- 1.60
- High
- 1.60
- Earnings
- Aug 25, 2026
Next earnings
Aug 25, 2026
Expected Aug 25, 2026. Consensus EPS estimate -0.01265.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Aug 25, 2026 | Jun 30, 2026 | -0.01265 | — | — | — |
| Apr 23, 2026 | Mar 31, 2026 | -0.02786 | 0.0087 | +0.04 | +131.23% |
| Mar 25, 2026 | Dec 31, 2025 | — | 0.05718 | — | — |
| Nov 13, 2025 | Sep 30, 2025 | — | -0.00281 | — | — |
| Aug 19, 2025 | Jun 30, 2025 | — | -0.00552 | — | — |
| May 13, 2025 | Mar 31, 2025 | — | 0.00138 | — | — |
News
- China's InnoCare, Eli Lilly sign collaboration deal worth up to $3.35 billion
- InnoCare Pharma Limited (INCPF) Q2 2026 Earnings Call Transcript
- China's Innocare's psoriasis drug meets main goal in late-stage trial
- InnoCare Announces First Patient Dosed in Clinical Trial of Novel CDH17 targeted ADC ICP-B208 in China
- Phase IIb Study Results of InnoCare's Orelabrutinib in Patients with SLE Presented at 2026 EULAR
- ASCO 2026 | Updated Data from an Oral Presentation of InnoCare's Novel BCL2 Inhibitor Mesutoclax in MDS and AML Released
- InnoCare Announces the Acceptance of New Drug Application for Orelabrutinib in Primary Immune Thrombocytopenia in China
- InnoCare Announces Approval of Orelabrutinib in Australia
- 2026 ASCO | Pivotal Data of InnoCare's Novel BCL2 Inhibitor Mesutoclax Released
- InnoCare Announce First Subject Dosed in Phase 1 Clinical Trial of ICP-054, a Novel Potentially Best-in-Class Oral IL-17AA/AF Inhibitor
Your note
Sign in to keep a note on INCPF — it syncs with the Stock Master app.